Gemcitabine is used in combination with carboplatin to treat ovarian cancer (cancer that begins in the female reproductive organs where eggs are formed) that returned at least 6 months after finishing a previous treatment. It also used in combination with paclitaxel (Abraxane, Taxol) to treat breast cancer that has not improved or that has worsened after treatment with other medications. Gemcitabine is used in combination with cisplatin to treat a type of lung cancer (non-small cell lung cancer; NSCLC) that has spread to other parts of the body and cannot be treated with surgery. Gemcitabine is also used to treat pancreatic cancer that has spread to other parts of the body and has not improved or worsened after treatment with another medication. Gemcitabine is in a class of medications called antimetabolites. It works by slowing or stopping the growth of cancer cells in the body.
Market Analysis and Insights: Global Gemcitabine Injection Market
Due to the COVID-19 pandemic, the global Gemcitabine Injection market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, 200mg/5.26 mL accounting for % of the Gemcitabine Injection global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Gemcitabine Injection market size is valued at US$ million in 2021, while the US and Europe Gemcitabine Injection are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Gemcitabine Injection landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Gemcitabine Injection include Fresenius Kabi, Teva Pharmaceuticals, Pfizer, Mylan Inc, Novartis AG, Accord Healthcare and Meitheal Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Gemcitabine Injection Scope and Segment
Gemcitabine Injection market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Gemcitabine Injection market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
200mg/5.26 mL
1g/26.3 mL
2g/52.6 mL
Segment by Application
Hospital
Clinic
By Company
Fresenius Kabi
Teva Pharmaceuticals
Pfizer
Mylan Inc
Novartis AG
Accord Healthcare
Meitheal Pharmaceuticals
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE